Abstract
Aumolertinib is a novel third-generation epidermal growth factor receptor (EGFR)-targeted oral tyrosine kinase inhibitor (TKIs). The positive phase III trial (AENEAS) reported objective response rate (ORR) was 73.8% and medium progression-free survival (mPFS) was 19.3 months which aumolertinib as 1st line treatment of patients with EGFR mutation Non-Small Cell Lung Cancer (NSCLC). An improved efficacy of the combination of first-generation EGFR-TKI and carboplatin plus pemetrexed was confirmed in NEJ009 study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
